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Abstract To evaluate the current practice and change in
practice concerning screening for distant metastases in
head and neck squamous cell carcinoma patients, we per-
formed a survey with the same questionnaire as 10 years
ago among the eight centers of the Dutch Head and Neck
Society treating head and neck cancer in The Netherlands.
Factors related to extensive lymph node metastases are the
most frequent indication for screening for distant metas-
tases. The combinations of whole body PET-CT and con-
trast-enhanced chest CT are nowadays the diagnostic
techniques for routinely screening for distant metastases.
Screening for distant metastases is performed more fre-
quently than 10 years ago. Although the sensitivity of the
diagnostic pathway needs to be improved, most centers are
satisfied with the current diagnostic pathway. A reduction
of variation in indications and diagnostic techniques used
for screening for distant metastases is observed during the
last 10 years. In future guidelines patients’ selection and
diagnostic tests need to be specified in more detail.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) have
a tendency to metastasize to regional lymph nodes rather
than to spread hematogeneously to distant sites. The
incidence of distant metastases is directly related to the
stage of the tumour, particularly the presence and exten-
sion of lymph node metastases, and regional control
above the clavicles. Once distant metastases have been
detected, the prognosis is dismal. The median time to
death from the diagnosis of distant metastases ranges
1–12 months. About 88 % of patients with distant
metastases will die within 12 months. Thus, the detection
of distant metastases is critical for prognostication and for
the choice of treatment in patients with HNSCC. Patients
with known distant metastatic disease can possibly be
spared the toxicities of aggressive and often unnecessary
locoregional therapy [1].
Ten years ago, we performed a survey which showed a
substantial variation in indications and diagnostic tech-
niques used for pretreatment screening for distant metas-
tases between the major institutions treating head and neck
cancer in The Netherlands. Eight of 19 (42 %) clinicians
stated that they were not satisfied with the current course of
diagnostic investigations, because of a perceived lack of
sensitivity of the current tests [2]. In these 10 years,
diagnostic techniques improved and PET-CT became
wider available.
Since then an update of the Dutch guidelines on laryn-
geal carcinoma (version 3.0, 2010) of the Dutch Head and
Neck Society (NWHHT) was published (oncoline.nl) in
which it was stated that screening by chest CT was indi-
cated in patients with three or more lymph node metas-
tases, low jugular metastases and N2c or N3 disease. In the
recent version of the Dutch NWHHT guidelines for head
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and neck cancer it is advised to perform FDG-PET-CT in
high risk HNSCC patients.
To evaluate the current practice and change in practice
concerning the diagnostic work-up in HNSCC patients, we
performed a survey with the same questionnaire as
10 years ago among the eight centers of the Dutch Head
and Neck Society treating head and neck cancer in The
Netherlands.
Materials and methods
Ethical considerations: no ethical approval was needed for
this survey on the routine clinical practice.
The questionnaire on current clinical practice concern-
ing screening for distant metastases in HNSCC patients
was sent to eight head and neck surgeons as representatives
of the eight head and neck centers of the Dutch Head and
Neck Society (NWHHT) treating head and neck cancer in
The Netherlands. The questionnaire (Fig. 1) was accom-
panied by an explanatory mail.
Results
The response rate was 100 %. Indications for screening for
distant metastases are summarized in Table 1. In Table 2
indications for screening for distant metastases related to
lymph node metastasis were specified. In one center all N?
patients undergo screening for distant metastases. The
results of the question which techniques (besides chest
X-ray) are routinely used for screening are shown in
Table 3.
Two (25 %) clinicians reported screening in 11–20
patients annually and 6 (75 %) performed screening for
distant metastases in more than 20 patients.
If a patient with HNSCC could only be cured by
extensive surgery, the number of clinicians that would have
refrained from curative surgery and resorted to palliative
measures if they considered that the patient would develop
distant metastases, within a certain period was 7 (88 %) for
distant metastases within 3 months after surgery, 7 (88 %)
for 3–6 months, 6 (75 %) for 6–12 months and 2 (25 %)
for 12–24 months after surgery. One center could not
answer this question because it ‘‘depends on many factors
like actual complaints caused by the tumor, co-morbidity,
patient preferences, expected functional outcome of the
procedure, etc.’’.
Six (75 %) centers were satisfied with the current
diagnostic pathway. Two (25 %) centers stated that they
were not satisfied with the current course of diagnostic
investigations, because ‘‘Dilemma between routinely per-
forming chest X-ray or CT (in head and neck cancer
patients in general)’’ and ‘‘Financial problems (like to do
more chest CT and/or PET-CT)’’.
Discussion
In 10 years’ time the clinical practice of screening for
distant metastases has changed: extensive lymph node
metastases is the main indication for pretreatment screen-
ing of distant metastases, FDG-PET-CT combined with
contrast-enhanced chest CT is the current screening tech-
nique and most centers are satisfied with current diagnostic
pathway.
The incidence of distant metastases from HNSCC at
presentation is generally too low to warrant routinely
extensive radiological screening for distant metastases in
all HNSCC patients. Therefore, high risk factors have been
identified and validated: three or more lymph node
metastases, bilateral lymph node metastases, lymph nodes
larger than 6 cm, low jugular lymph node metastases,
regional tumour recurrence and second primary tumours [3,
4]. Another radiological high risk factor is extra nodal
spread [5]. Most of the centers use these criteria, although
some centers simplified these factors using N2-N3 disease
as indication for screening for distant metastases. Some
indications do not harbor a high risk of distant metastases,
but may be justified if the morbidity of a planned treatment
or burden to the patient is very high, e.g., extremely
mutilating surgery.
While 10 years ago several diagnostic techniques were
used, currently PET-CT and contrast enhanced chest CT
are the only techniques and are used in almost all centers
routinely. This combination of PET-CT and contrast-en-
hanced chest CT is the best strategy to screen for distant
metastases [6, 7]. In a meta-analysis Xu et al. [8] found for
integrated PET-CT a pooled sensitivity and specificity to
detect distant metastases of 88 and 95 %, respectively.
However, about half of the high risk patients develop dis-
tant metastases during follow-up, despite negative screen-
ing by PET-CT. Therefore, room for improvement remains.
Due to technical improvement whole body MRI is feasible
[9] and studies in these high risk HNSCC patients com-
paring this new technique with the current best technique,
i.e., PET-CT (including contrast enhanced chest CT), are
needed.
All centers would refrain from extensive treatment if a
HNSCC patient would develop clinically manifest distant
metastases within 6 months, except one center which
makes the decision to treat with curative intent dependent
on many factors like actual complaints caused by the
tumor, co-morbidity, patient preferences and expected
functional outcome of the procedure. Almost all centers
would only offer treatment with curative intent if
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Questionnaire on current practice concerning diagnostic work-up
Q. 1: What indications do you use to screen for distant metastases in patients without specific 
complaints or symptoms and with a normal X-thorax and blood tests?                              
(more than 1 answer allowed)
o T-stage 3-4
o advanced N-stage, i.e.:……..
o localisation of  lymph nodes in the neck, i.e.:…….
o surgical intervention for a local recurrence
o surgical intervention for a second primary HNSCC
o extremely mutilating surgical intervention
o clinically 3 or more lymph node metstaseas
o low jugular lymph node metastases
o bilateral lymph node metastases
o metastases of 6 cm or larger
o local recurrence
o regional recurrence
o second primary head and neck cancer
o radiological extra nodal spread
o none, I never screen
o other, i.e.:………
Q. 2: When you decide to perform screening, which technique(s) do you use?( more than 1 
answer allowed)
o none, I never screen
o X-thorax
o CT scan of the thorax
o ultrasound of the liver
o CT scan of the liver
o bone scintigraphy
o PET scan
o PET-CT (low dose CT)
o PET-CT (diagnostic contrast enhanced CT)
o Whole body MRI
o other, i.e.: …………………………………




o > 20 times, i.e.:………..
Q. 4: In a patient who is being considered for a extensive surgical intervention, when would you 
decide not to perform this surgery, but to treat the patient palliatively?
o If  I would know that distant metastases would become clinically evident within 3 
months after treatment
o If  I would know that distant metastases would become clinically evident within 3 to 6 
months after treatment
o If  I would know that distant metastases would become clinically evident within 6 to 12 
months after treatment
o If  I would know that distant metastases would become clinically evident within 12  to 
24 months after treatment
Explanation -
What we intended with this question was to name a subtle distinction in this dilemma: if  you 
want to treat a patient with curative surgery for, for example, a T3N1 oropharyngeal 
carcinoma, but preoperatively this patient turns out to have distant metastases, most 
surgeons will refrain from surgery and choose for a palliative treatment. On the other hand, 
when distant metastases become clinical evident after 2 years, nobody will regret having 
performed surgery. 
We wanted to find out where the subtle distinction between operating and refraining from 
surgery lies.
Q. 5: Are you satisfied with the current diagnostic pathway?
o yes
o no, because…………………
Fig. 1 Questionnaire on current
practice concerning diagnostic
work-up
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development of distant metastases are expected not to be
within 12 months.
Pretreatment screening for distant metastases is per-
formed more frequently: 75 % of head and neck centers
more than 20 times a year, in comparison with 26 % of
clinicians 10 years ago. Ten years ago 42 % of the clini-
cians stated that they were not satisfied with the course of
diagnostic investigations, because of a perceived lack of
sensitivity of the tests at that moment. Although nowadays
the sensitivity of the best diagnostic technique, i.e., PET-
CT, is still limited, none of the centers mentioned to be
dissatisfied by the performance of the diagnostic tests. One
center was not satisfied because of the dilemma to perform
routinely chest X-ray or CT. However, plain chest X-ray
films detect only a minority of all malignant pulmonary
lesions detected by CT. Another center has a financial
problems with this diagnostic pathway, because the
physicians like to do more chest CT and/or PET-CT.
Although FDG-PET is an expensive diagnostic test, the
detection of distant metastases can avoid futile expensive
treatments. When applied in the pre-treatment work-up of
high risk HNSCC the addition of FDG-PET did not lead to
additional costs [10]. Moreover, PET-CT is nowadays
commonly used for radiation treatment planning.
Through the response rate of 100 % and the centralized
care for head and neck cancer patients the clinical practice
the entire Netherlands is covered by this survey. The same
questionnaire as 10 years ago was used making comparison
possible.
In the previous survey individual physicians from all
eight centers instead of one representative per center were
asked limiting direct comparison between both surveys to
some extent.
This survey shows a reduction of variation in indications
and diagnostic techniques used for screening for distant
metastases between the Dutch centers treating head and
neck cancer in The Netherlands over the last 10 years.
Although the sensitivity of FDG-PET-CT is limited the
physicians in most centers are satisfied with the policy to
screen HNSCC patients with extensive lymph node
involvement routinely by whole body FDG-PET-CT and
Table 1 Results relating to question about indications for screening for distant metastases
Indication Responders Specifications
2005 (n = 19) 2015 (n = 8) 2005 2015
Lymph node metastasis 12/19 (63 %) 8/8 (100 %) CN2b, levels, IV–V, supraclavicular See Table 2
Extremely mutilating surgical intervention 11/19 (58 %) 5/8 (63 %)
Local and/or regional recurrence 9/19 (47 %) 4/8 (50 %)
T-stage 3–4 6/19 (32 %) 1/8 (13 %)
Second primary head and neck cancer 4/19 (21 %) 3/8 (38 %)
Table 2 Indications for
screening for distant metastases
related to lymph node
metastasis
Indication Responders (n = 8)
Advanced N-stage (N2–N3) 5a (63 %)
Localisation of lymph nodes in the neck (Level V) 4 (50 %)
Clinically three or more lymph node metastases 6 (75 %)
Low jugular lymph node metastases 7 (88 %)
Bilateral lymph node metastases 7 (88 %)
Metastases of 6 cm or larger 8 (100 %)
Regional recurrence 3 (38 %)
Radiological extra nodal spread 2 (25 %)
a In one center not N2a
Table 3 Results relating to question which techniques are routinely
used besides chest X-ray
Diagnostic technique Responders
2005 (n = 19) 2015 (n = 8)
Contrast enhanced chest CT 16/19 (84 %) 7/8 (88 %)
Ultrasound liver 10/19 (53 %)
CT liver 3/19 (16 %)
Bone scintigraphy 8/19 (42 %)
PET(-low dose CT) 13/19 (68 %)a 8/8 (100 %)b
a Only in research protocol
b In one center only in selected cases
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contrast-enhanced chest CT. In future guidelines patients’
selection and diagnostic tests need to be specified in more
detail.
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